News | May 16, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Strengthening capabilities in Peptide Therapeutics and CDMO services
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Subscribe To Our Newsletter & Stay Updated
